더바이오 10월 7일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=658](https://www.thebionews.net/edit/webzine.html?idxno=658) ●동아제약 ‘제2 전성기’ 노리는 오너 3세 강정석 회장…첫 영업익 1000억 눈앞 [https://www.thebionews.net/news/articleView.html?idxno=28786](https://www.thebionews.net/news/articleView.html?idxno=28786) ●“GLP-1 확산으로 ‘오젬픽 페이스’ 부각…미용의료 수요 키운다” [https://www.thebionews.net/news/articleView.html?idxno=28791](https://www.thebionews.net/news/articleView.html?idxno=28791) ●[인터뷰] 日 신약 피칭대회 우승 빌릭스, ‘빌리루빈 신약’으로 신장손상 예방·치료 도전 [https://www.thebionews.net/news/articleView.html?idxno=28792](https://www.thebionews.net/news/articleView.html?idxno=28792) ●美 마드리갈, ‘레즈디프라’ MASH 진행 관련 유전적 위험 변이에도 효과 일관 [https://www.thebionews.net/news/articleView.html?idxno=28790](https://www.thebionews.net/news/articleView.html?idxno=28790) ●알테오젠 ALT-B4 적용 ‘젬퍼리SC’ 임상 간다…GSK, 11월 시작 예고 [https://www.thebionews.net/news/articleView.html?idxno=28815](https://www.thebionews.net/news/articleView.html?idxno=28815) ●지아이이노베이션, ‘레시게르셉트’ 일본 임상2상 본격화…10월 첫 환자 투약 [https://www.thebionews.net/news/articleView.html?idxno=28794](https://www.thebionews.net/news/articleView.html?idxno=28794) ●임상 실패 이유?…샤페론 “누겔 포장 위탁업체, 활성약·위약 코드 기재 오류” [https://www.thebionews.net/news/articleView.html?idxno=28828](https://www.thebionews.net/news/articleView.html?idxno=28828) ●HLB, 담관암 신약 ‘리라푸그라티닙’ 유럽 허가 본심사 착수 [https://www.thebionews.net/news/articleView.html?idxno=28800](https://www.thebionews.net/news/articleView.html?idxno=28800) ●美 카리부, 동종 CAR-T 세포치료제 2종 개발 중단 계획…전략적 대안 검토 [https://www.thebionews.net/news/articleView.html?idxno=28816](https://www.thebionews.net/news/articleView.html?idxno=28816) ●美아리벤트 “퍼모너티닙, EGFR 엑손20 폐암 1차 치료 3상서 PFS 개선 실패” [https://www.thebionews.net/news/articleView.html?idxno=28814](https://www.thebionews.net/news/articleView.html?idxno=28814) ●할로자임·아르젠엑스, ‘ENHANZE’ 협력 확대…SC제형 타깃 2개 추가, 총 8개 [https://www.thebionews.net/news/articleView.html?idxno=28813](https://www.thebionews.net/news/articleView.html?idxno=28813) ●셀트리온, 악템라 시밀러 ‘앱토즈마’ 美 소아 코로나19 적응증 추가 승인 획득 [https://www.thebionews.net/news/articleView.html?idxno=28804](https://www.thebionews.net/news/articleView.html?idxno=28804) ●HLB펩 스킨케어 ‘랩센’, 루마니아 수출로 유럽시장 첫 진출 [https://www.thebionews.net/news/articleView.html?idxno=28824](https://www.thebionews.net/news/articleView.html?idxno=28824) ●삼성바이오로직스 “엔드 투 엔드 CDMO 서비스로 APAC 시장 공략 가속” [https://www.thebionews.net/news/articleView.html?idxno=28818](https://www.thebionews.net/news/articleView.html?idxno=28818) ●지씨셀, CAR-NK 후보물질 ‘GCC2005’ 임상1b상 돌입…첫 환자 투약 완료 [https://www.thebionews.net/news/articleView.html?idxno=28807](https://www.thebionews.net/news/articleView.html?idxno=28807) ●씨엔알리서치, 美 나스닥 상장사 ‘원메드넷’과 의료데이터 공급계약 체결 [https://www.thebionews.net/news/articleView.html?idxno=28808](https://www.thebionews.net/news/articleView.html?idxno=28808) ●셀비온, ‘바이오재팬’ 출격…“글로벌 파트너링 확대” [https://www.thebionews.net/news/articleView.html?idxno=28805](https://www.thebionews.net/news/articleView.html?idxno=28805) ●고려대안암병원 김동현 교수, 안구건조증 신약 후보물질 임상2상 맡아 [https://www.thebionews.net/news/articleView.html?idxno=28801](https://www.thebionews.net/news/articleView.html?idxno=28801) ●JW중외제약, 약국 전용 온라인몰 ‘JWSHOP’ 주문·배송 편의성 강화 [https://www.thebionews.net/news/articleView.html?idxno=28802](https://www.thebionews.net/news/articleView.html?idxno=28802) ●‘몸속에서 직접 암치료제 만든다’…서울대기술지주, ‘엠브릭스’에 투자 [https://www.thebionews.net/news/articleView.html?idxno=28797](https://www.thebionews.net/news/articleView.html?idxno=28797) ●Xcell Therapeutics: “Two-track approach of CGT media and recombinant collagen – Corporate value proven by results” [https://www.thebionews.net/news/articleView.html?idxno=28827](https://www.thebionews.net/news/articleView.html?idxno=28827) ●CellBion wins Korea Phase 3 approval for prostate cancer candidate ‘177Lu-DGUL,’ accelerates commercialization [https://www.thebionews.net/news/articleView.html?idxno=28826](https://www.thebionews.net/news/articleView.html?idxno=28826) ●Inventage Lab files PCT for ultra-high concentration antibody SC platform, unveils research results at U.S. PODD [https://www.thebionews.net/news/articleView.html?idxno=28825](https://www.thebionews.net/news/articleView.html?idxno=28825) ●Celltrion to join ‘CPHI 2026’ in October, seeks global partners for new drugs and CDMO [https://www.thebionews.net/news/articleView.html?idxno=28823](https://www.thebionews.net/news/articleView.html?idxno=28823) ●AbClon: “China’s Henlius Biotech launches ‘AC101’ trials in colorectal cancer and ADC-resistant breast cancer” [https://www.thebionews.net/news/articleView.html?idxno=28822](https://www.thebionews.net/news/articleView.html?idxno=28822) ●HLB Panagene presents PNA research achievements at U.S. nucleic acid therapeutics conference ‘OTS 2026’ [https://www.thebionews.net/news/articleView.html?idxno=28821](https://www.thebionews.net/news/articleView.html?idxno=28821) ●NEX-I targets ‘operating profit’ by 2028, pins hopes on lead asset ‘NXI-201’ [https://www.thebionews.net/news/articleView.html?idxno=28820](https://www.thebionews.net/news/articleView.html?idxno=28820) ●Coreline Soft signs ‘AVIEW CAC’ supply agreement with Japan’s M3 AI [https://www.thebionews.net/news/articleView.html?idxno=28819](https://www.thebionews.net/news/articleView.html?idxno=28819) *제약바이오 10월 7일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=oYnxiYSCG0c](https://www.youtube.com/watch?v=oYnxiYSCG0c)